2022
Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening
Leapman MS, Wang R, Park H, Yu JB, Sprenkle PC, Cooperberg MR, Gross CP, Ma X. Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening. JAMA Oncology 2022, 8: 41-47. PMID: 34762100, PMCID: PMC8587214, DOI: 10.1001/jamaoncol.2021.5143.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCohort StudiesEarly Detection of CancerHumansMaleMass ScreeningMiddle AgedProstate-Specific AntigenProstatic NeoplasmsRetrospective StudiesConceptsProstate cancer screeningUS Preventive Services Task ForcePSA testingCancer screeningInterrupted time series analysisCohort studyUS Preventive Services Task Force (USPSTF) recommendationDraft statementLarge national cohort studyEligible beneficiariesPSA testing ratesRetrospective cohort studyRate of PSANational cohort studyProstate-specific antigenAge-adjusted ratesTask Force recommendationsUSPSTF guidelinesMedian ageGuideline changesProstate cancerMedian numberMAIN OUTCOMEClaims dataTesting rates
2020
Trends in Use and Comparison of Stereotactic Body Radiation Therapy, Brachytherapy, and Dose-Escalated External Beam Radiation Therapy for the Management of Localized, Intermediate-Risk Prostate Cancer
Nguyen KA, Lee A, Patel SA, Chakravorty A, Yu JB, Kishan AU, Chang AJ. Trends in Use and Comparison of Stereotactic Body Radiation Therapy, Brachytherapy, and Dose-Escalated External Beam Radiation Therapy for the Management of Localized, Intermediate-Risk Prostate Cancer. JAMA Network Open 2020, 3: e2017144. PMID: 32970153, PMCID: PMC7516602, DOI: 10.1001/jamanetworkopen.2020.17144.Peer-Reviewed Original ResearchConceptsStereotactic body radiation therapyBody radiation therapyRadiation therapyProstate cancerIntermediate-risk prostate cancerExternal beam radiation therapyManagement of LocalizedExternal beam radiotherapyUse of brachytherapyBeam radiation therapyCohort studyBeam radiotherapyTherapyDisease managementCancerBrachytherapyPatientsRadiotherapyGeographic-Level Association of Contemporary Changes in Localized and Metastatic Prostate Cancer Incidence in the Era of Decreasing PSA Screening
Yang DX, Makarov DV, Gross CP, Yu JB. Geographic-Level Association of Contemporary Changes in Localized and Metastatic Prostate Cancer Incidence in the Era of Decreasing PSA Screening. Cancer Control 2020, 27: 1073274820902267. PMID: 32003227, PMCID: PMC7003204, DOI: 10.1177/1073274820902267.Peer-Reviewed Original ResearchMeSH KeywordsAgedEarly DiagnosisHumansIncidenceMaleMass ScreeningProstate-Specific AntigenProstatic NeoplasmsConceptsMetastatic prostate cancer incidenceProstate cancer incidenceHealth care service areasMetastatic diseaseCancer incidenceNational Cancer Institute's SurveillanceEnd Results (SEER) databaseLocalized prostate cancerSEER 18 registriesProstate-specific antigenPSA screeningLocalized diseaseResults databaseProstate cancerOlder menMetastatic incidenceIncidenceDiseaseDiagnosisLate changesMenRecent increaseAssociationRegistryCancer
2019
Conservative management of low‐risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database
Mahal A, Butler S, Franco I, Muralidhar V, Larios D, Pike L, Zhao S, Sanford N, Dess R, Feng F, D’Amico A, Spratt D, Yu J, Nguyen P, Rebbeck T, Mahal B. Conservative management of low‐risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database. Cancer 2019, 125: 3338-3346. PMID: 31251398, DOI: 10.1002/cncr.32332.Peer-Reviewed Original ResearchConceptsLow-risk prostate cancerPositive biopsy coresShort-term outcomesBiopsy coresProstate cancerManagement of low-risk prostate cancerOlder patientsProstate cancer-specific mortality ratesConservative managementProstate cancer-specific mortalityCancer-specific mortality ratesActive surveillance/watchful waitingRate of conservative managementOlder menCancer-specific mortalityShort-term safetyQuality-of-life implicationsDefinitive treatmentYounger patientsOverall mortalityPatientsMortality rateProstateNational databaseCancer
2017
Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States
Mahal B, Chen Y, Muralidhar V, Mahal A, Choueiri T, Hoffman K, Hu J, Sweeney C, Yu J, Feng F, Kim S, Beard C, Martin N, Trinh Q, Nguyen P. Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. Annals Of Oncology 2017, 28: 1098-1104. PMID: 28453693, DOI: 10.1093/annonc/mdx041.Peer-Reviewed Original ResearchConceptsProstate cancer-specific mortalityProstate-specific antigenUnited States Preventive Services Task ForceRisk of prostate cancer-specific mortalityProstate cancer outcomesBlack raceMetastatic diseaseCancer outcomesProstate-specific antigen screeningRate of metastatic diseasePSA screening guidelinesCancer-specific mortalityRisk of poor outcomesStage of presentationPreventive Services Task ForceScreening-eligible ageMultivariate logistic regressionEligible populationNon-black menSEER databaseProstate cancerBlack menScreening guidelinesPoor outcomeRisk regression
2016
Weighing Risk of Cardiovascular Mortality Against Potential Benefit of Hormonal Therapy in Intermediate-Risk Prostate Cancer
Lester-Coll N, Johnson S, Magnuson W, Goldhaber S, Sher D, D'Amico A, Yu J. Weighing Risk of Cardiovascular Mortality Against Potential Benefit of Hormonal Therapy in Intermediate-Risk Prostate Cancer. Journal Of The National Cancer Institute 2016, 109: djw281. PMID: 28040795, DOI: 10.1093/jnci/djw281.Peer-Reviewed Original ResearchConceptsIntermediate-risk prostate cancerQuality-adjusted life yearsHormone therapyHistory of myocardial infarctionCardiac risk factorsBiochemical failureProstate cancerRadiation therapyCardiac riskProbability of biochemical failureMonths of hormone therapyRisk factorsMyocardial infarctionYears of follow-upBenefits of HTRisk of cardiovascular mortalityDisease recurrence riskCardiac risk groupsComparing quality-adjusted life-yearsYoung menRecurrence riskFollow-upRisk groupsCardiovascular mortalityLow riskIncorporating Androgen Deprivation With Dose-Escalated External-Beam Radiotherapy for Prostate Cancer
Dosoretz A, Yu J. Incorporating Androgen Deprivation With Dose-Escalated External-Beam Radiotherapy for Prostate Cancer. Journal Of Clinical Oncology 2016, 34: 1718-1722. PMID: 27001587, DOI: 10.1200/jco.2015.66.3237.Peer-Reviewed Original ResearchMeSH KeywordsAgedAndrogen AntagonistsCombined Modality TherapyHumansMaleNeoplasm GradingProstate-Specific AntigenProstatic NeoplasmsRadiotherapy DosageConceptsExternal-beam radiotherapyDigital rectal examinationPalpable diseaseRectal examinationGleason 3+3 diseaseOncology Grand Rounds seriesHigh-grade prostate cancerMagnetic resonance imaging-ultrasound fusionMultiparametric magnetic resonance imagingAdjacent normal prostatePositive biopsy coresUltrasound-guided biopsyInguinal hernia repairT2-weighted imagesJournal of Clinical OncologyPatient's medical historyMagnetic resonance imagingHypointense featuresGleason 4Prostate volumePSA levelsAndrogen deprivationCataract surgeryIntraprostatic lesionsBiopsy cores